Targeting PD-L1 degradation, inhibiting CD47 expression, and preventing Y239/Y240 ShcA phosphorylation by using specific drugs, should allow tumor immune suppression to be contrasted differently from PD1-PD-L1 inhibitors. The gene discussed is CD47; the disease is neoplasm.